The Zhitong Finance App learned that German private biotech company Disco Pharmaceuticals said on Thursday that ABBV.US (ABBV.US) agreed to pay up to 2.54 billion US dollars to jointly develop cancer treatments with Disco, which marks the pharmaceutical company's early layout for the next generation of bispecific antibody therapy.
Bispecific antibodies are a class of cancer drugs that can combine two targets at the same time, and have attracted growing interest from large pharmaceutical companies including Bristol-Myers Squibb (BMY.US), Pfizer (PFE.US), and Merck (MRK.US).
In January of this year, AbbVie paid an advance payment of 650 million US dollars to Rongchang Biology (RemeGen) to obtain the benefits of a bispecific drug for solid tumors outside of China.
As part of this partnership, Disco will receive an advance payment of $40 million and a milestone payment of up to $2.5 billion to develop so-called “AND-gated” (AND-gated) bispecific therapies for solid tumors. It also qualifies for tiered sales shares based on global net sales.
The design idea of this method is that cancer cells are only recognized when the two target proteins are present at the same time, which may reduce damage to healthy tissue.
Disco CEO Mark Manfredi said his company will be responsible for the research and discovery process. AbbVie will have the exclusive right to license the selected project for subsequent development.
Manfredi said, “(AbbVie) brought a wealth of information and rich experience in target biology, so we will learn from them and work with them to determine how to select targets.”
The deal is in a very early stage. Disco did not disclose how many projects it may cover or when it will enter clinical development, and AbbVie's licensing options only take effect after Disco has completed the designated studies.
Disco has been developing gated therapies for small cell lung cancer and colorectal cancer. Manfredi said the company will select a drug candidate for development in the second half of next year.
Other recent bispecific antibody deals include a partnership of up to $11.1 billion between Bristol-Myers Squibb and BioNTech (BNTX.US), a multi-billion dollar deal between Takeda (Takeda) and China's Innovent (Innovent), and UCB (UCB)'s $2.2 billion acquisition of Candid Therapeutics.